Clinical TrialsContext Therapeutics is progressing with two T cell engaging bispecific antibodies, CTIM-76 and CT-95, in Phase 1 clinical trials for solid tumors.
Financial StabilityContext remains well-capitalized with $94.4M in cash, providing financial stability and runway into 2027.
Project ManagementDevelopment timelines for key projects CTIM-76 and CT-95 remain on track, indicating strong project management and potential for future growth.